Clinical Trial
Study Details
Matching placebo capsule. Administered orally once a day on dosing days.
HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
The purpose of this study is to assess the safety and tolerability of HQK-1001 administered for a total of 12 weeks (with one dosing break) in subjects with sickle cell disease.
Study Overview
Contacts and Locations
Trialogic Research
Madison, Alabama 35758
United States
Children's Hospital and Research Center at Oakland
Oakland, California 94609
United States
Century Clinical Research, Inc.
Daytona Beach, Florida 32117
United States
Medical College of Georgia
Augusta, Georgia 30912
United States
University of Illinois at Chicago
Chicago, Illinois 60612
United States
Johns Hopkins School of Medicine
Baltimore, Maryland 21205
United States
UNC Comprehensive Sickle Cell Program
Chapel Hill, North Carolina 27599
United States
Texas Children's Cancer Center and Hematology Service
Houston, Texas 77030
United States
University of the West Indies, Mona
Kingston
Mona
Jamaica